Cardiotoxicity

New Stem Cell Technology to Improve Drug Safety

...even millions of patients. Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current cardiotoxicity tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function -- the hERG ion channel. But there are a who...

Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer

...- Ana Maria Gonzalez-Angulo, MD, MSc, of The University of Texas M. D. Anderson Cancer Center, will discuss the issue anthracycline related cardiotoxicity Physicians can register for and take this accredited, virtual e-conference course at any time beginning Tuesday, October 14, 2008 at http://www.virt...

Also in the July 29 JNCI

...pirubicin dose associated with a 5 percent risk of cardiotoxicity for individual patients. Oncologists frequently...he researchers assessed patients' risk factors for cardiotoxicity and corrected for the risk of death from all other...re of the risk of cardiotoxicity, not only because cardiotoxicity can progress to a potentially fatal outcome if not...

Genetic Engineering and Biotechnology News reports on early ADMET use

...otential but also cardiotoxicity. The company introduced the use of neonate rat cardiomyocytes cultured in 96-well plates to monitor the potential for cardiotoxicity of a drug candidate. Other companies covered in the GEN article include Affymetrix, Iconix, Sovicell, Apredica, MatTek, ChanTest, and EggCentris. ...

Cardiotoxicity in Medical Technology

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

...difications are also hypothesized by the authors to underlie the drugs' low cardiotoxicity profile in preclinical animal studies when compared to standard anthracycli...ssive NHL as determined by the FDA, the failure of pixantrone to have a low cardiotoxicity profile or to produce low cardiac toxicity, the failure of pixantrone to pr...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

...0.67, favoring Amrubicin. The most common adverse events were hematological and were generally equal between the two arms. No classical anthracycline cardiotoxicity has been observed to date, supporting data from earlier Japanese studies that suggest Amrubicin may be devoid of this anthracycline-associated adverse...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... as a paronychial inflammation. The safety of ERBITUX in combination with radiation therapy and cisplatin has not been established. Death and serious cardiotoxicity were observed in a single-arm trial with ERBITUX, delayed, accelerated (concomitant boost) fractionation radiation therapy, and cisplatin (100 mg/m2) ...

Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting

...----------------------------------- ----------------------- ---------------------------------------------- Presentation Title: "Reduced chronic cardiotoxicity and mitochondrial damage of the (6- maleimidocaproyl) hydrazone derivative of ...

Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program

...icin group having a high cardiomyopathy score of seven These data suggest that the proposed Phase II dose of 200 mg/m2 should demonstrate mild to no cardiotoxicity in patients. Innovive intends to initiate a Phase II study in Small Cell Lung Cancer in Q207. About INNO-206 INNO-206 (formerly DOXO-EMCH) is a do...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

...showed higher effectiveness and minimal or lack of cardiotoxicity as compared to mitoxantrone or doxorubicin. The fi...ted with doxorubicin and to evaluate the potential cardiotoxicity of pixantrone as a single agent compared to doxoru...the second cycle had slightly increased mean total cardiotoxicity score, indicating that earlier exposure to doxorub...

Cardiotoxicity in Biological News

A search for protection against chemotherapy cardiotoxicity

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. The research article describing this work entitled Erythropoietin pretreatment protects against acute chemot...

Phylonix to present at 2009 Society of Toxicology Annual Meeting

...d Otoprotection in a Zebrafish Hair Cell Model" Tuesday, March 17, 10:36 am - 10:59 am, Room 308 Poster Presentations "Assessment of Drug Induced cardiotoxicity in Transparent Zebrafish" Monday, March 16, 1:00 pm - 4:30 pm 390 Poster / Board 207 "Zebrafish: A Predictive Model for Assessing P-Glycoprotein In...

American Chemical Society's Weekly PressPac -- April 23, 2008

...ave concluded in a new overview of research on the cardiotoxicity of anti-cancer drugs. Their review, scheduled for ...d Emanuela Salvatorelli point out that the risk of cardiotoxicity may be higher than previously believed, especially...ative efforts that improve early identification of cardiotoxicity and minimize the risks of cardiac events in patien...

Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design

...ple species. Singulex was the first to identify and quantify normal levels and small changes of cardiac troponin I, a protein biomarker used to detect cardiotoxicity and heart attacks, in human plasma. "Singulex's technology extends the clinical utility of new and existing biomarkers by removing the limits of det...

Cardiotoxicity in Biological Technology

Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement

MADISON, Wis., July 1 /PRNewswire/ -- Cellular Dynamics International (CDI) and Roche announced today a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration a...

Sopherion Therapeutics Secures $55 Million in Series C Funding

...inical development program for its lead product candidate, Myocet(TM). Myocet is a liposomal formulation of doxorubicin designed to reduce the risk of cardiotoxicity while preserving antitumor efficacy. In January 2008, Zoticon Bioventures in-licensed Myocet and provided funding of $20 million to Sopherion and...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

...nt-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class o... a liposomal delivery system for doxorubicin designed to reduce the risk of cardiotoxicity associated with doxorubicin while preserving its antitumor efficacy. It is...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

...on Therapy and Cisplatin -- The safety of ERBITUX in combination with radiation therapy and cisplatin has not been established - Death and serious cardiotoxicity were observed in a single-arm trial with ERBITUX, radiation therapy, and cisplatin (100 mg/m2) in patients with locally advanced squamous cell carcino...

First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA

...Disease-Free Survival (DFS) and Overall Survival (OS), compared to AC-T (doxorubicin and cyclophosphamide followed by docetaxel) and a 5-fold lower cardiotoxicity compared to AC-TH (AC-T + Herceptin) in women receiving adjuvant therapy for HER2-positive ESBC EDMONTON, Canada, May 29 /PRNewswire/...

Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates

...rdiac toxicity in new drugs at the World Pharmaceutical Congress in Philadelphia on May 12, 2008 when he gives a presentation entitled: "Evaluation of cardiotoxicity of Novel Molecular Therapies." "The topic of cardiac safety of new drugs is one that has long been a priority for pharmaceutical companies. Cardiac ...

ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America

...plates, and pre-seeded coverslips. Branded as Cor.AT cells, these cardiomyocytes have been rigorously functionally qualified and found to be ideal for cardiotoxicity screening, electrophysiology studies, and as a cellular model system for hypertrophic cardiomyopathy. Pure ventricular cardiomyocytes (Cor.VE) are als...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

...mood that resolved in a single day. Noticeably absent were toxicities associated with conventional chemotherapy, including alopecia, myelosuppression, cardiotoxicity and peripheral neuropathy. Accrual is continuing in this Phase 2 trial. Up to 20 additional patients are anticipated to be treated with the Injectab...